Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices

Maimon Working Papers

 Maimon Working Papers in formulary evaluations and health technology assessment present versions of papers that have been submitted to journals. These are typically extended versions of final publications, where for purposes of space and presentation they may have been modified for publication. The Maimon Working Papers are free to download (in PDF format).

Nullius in Verba: Truth is not Consensus
Working Paper No. 20 September 2021.pdf
Adobe Acrobat document [616.3 KB]
The Pursuit of Ignorance: The Institute for Clinical and Economic Review's Assessment of Tezepelumab for uncontrolled chronic asthma
Working Paper No. 19 September 2021.pdf
Adobe Acrobat document [776.7 KB]
More Nonsense on Stilts: Imaginary claims by the Institute for Clinical and Economic Review and the University of Illinoiss at Chicago, College of Pharmacy expert imaginary simulation group for the pricing of Eculizumab and Efgartigimod in myasthenia gravis
Working Paper No. 18 September 2021.pdf
Adobe Acrobat document [1'022.1 KB]
More Nonsense on Stilts: The Institute for Clinical and Economic Review's QALY companion - the myffic Equal Value of Life Years Metrics
Working Paper No. 17 September 2021.pdf
Adobe Acrobat document [906.2 KB]
Rejecting belief in Pseudoscience: A commitment in health technology assessment to meet normal science standards?
Working Paper No. 16 September 2021.pdf
Adobe Acrobat document [916.7 KB]
Next Generation Quality of Life Measures
Working Paper No. 15 August 2021.pdf
Adobe Acrobat document [926.9 KB]
Extended Nonsense from ICER: Changing Assumptions for Takhzyro and CI Inhibitors
Working Paper No. 14 August 2021.pdf
Adobe Acrobat document [708.5 KB]
Where Bliss in Ignorance: The Institute for Clinical and Economic Review (ICER), the Center for Pharmacoepidemiology and Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago and Imaginary Claims for Mavacamten in Hypertrophic Cardiomyopathy
Working Paper No. 13 August 2021.pdf
Adobe Acrobat document [869.7 KB]
Where Ignorance is Bliss: The Institute for Clinical and Economic Review (ICER), the University of Washington CHOICE Institute and atopic dermatitis simulation pricing and access recommendations
Working Paper No. 12 August 2021.pdf
Adobe Acrobat document [785.1 KB]
Veterans Affairs, the Institute for Clinical and Economic Review and generic health state eugenics
Working Paper No. 11 August 2021.pdf
Adobe Acrobat document [806.2 KB]
The Institute for Clinical and Economic Review's (ICER's) denial of Aducanumab in Alzheimer's disease
Working Paper No. 10 August 2021.pdf
Adobe Acrobat document [714.9 KB]
Abandoning Eugenics and the QALY
Working Paper No. 9 July 2021.pdf
Adobe Acrobat document [716.6 KB]
ISPOR Scores Its Technology Assessment Own Goal: Simulation models and Hume's problem of induction
Working Paper No. 8 June 2021.pdf
Adobe Acrobat document [771.5 KB]
Supping with the Devil: Belief and the imaginary worlds of multiple myeloma therapies invented by the Institute for Clinical and Economic Review
Working Paper No. 7 May 2021.pdf
Adobe Acrobat document [926.0 KB]
Peter Rabbit is a Badger in Disguise: Deconstructing the belief system of the Institute for Clinical and Economic Review in health technology assessment
Working Paper No. 6 May 2021.pdf
Adobe Acrobat document [911.8 KB]
A Commitment to Pseudoscience: Do we need probabilistic sensitivity analysis?
Working Paper No. 5 April 2021.pdf
Adobe Acrobat document [674.7 KB]
Flogging a Dead Horse: A-Mapping we will go
Working Paper No. 4 April 2021.pdf
Adobe Acrobat document [602.1 KB]
The Herd and the Meme: Why ordinary scales have to be ratio measures in disguise
Working Paper No. 3 April 2021.pdf
Adobe Acrobat document [585.7 KB]
The Poverty of Multiattribute Utility Scales
Working Paper No. 2 February 2021.pdf
Adobe Acrobat document [803.7 KB]
Deprogramming the Rabbit Hole of Technology Assessment
Working Paper No. 1 February 2021.pdf
Adobe Acrobat document [820.4 KB]
ICER Analytics: Fair Prices for Fun and Profit
Working Paper No. 29 December 2020.pdf
Adobe Acrobat document [721.6 KB]
Innovations in Medicaid Drug Utilization Reviews: Claims submission standards to support value based contracting
Working Paper No. 28 December 2020.pdf
Adobe Acrobat document [765.3 KB]
Let a Thousand Imaginary Models Bloom: ICER opens the floodgates to pseudoscience
Working Paper No. 27 December 2020.pdf
Adobe Acrobat document [1.1 MB]
Why ICER has failed
Working Paper No. 26 November 2020.pdf
Adobe Acrobat document [990.3 KB]
To Dream the Impossible Dream: The commitment by the Institute for Clinical and Economic Review to rewrite the axioms of fundamental measurement for Hemophilia A and Bladder Cancer value claims
Working Paper No. 25 November 2020.pdf
Adobe Acrobat document [1.2 MB]
More ICER nonsense on severe hemophilia A: The University of Illinois modelled evidence report for valoctocogene roxapavovec and emicizumab
Working Paper No. 24 October 2020.pdf
Adobe Acrobat document [983.6 KB]
Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines
Working paper No. 23 October 2020.pdf
Adobe Acrobat document [1.1 MB]
More Covid-19 Nonsense: The ICER modelled threshold price benchmarks for Remdesivir
Working Paper No. 22 October 2020.pdf
Adobe Acrobat document [708.6 KB]
Formulary Design, Fair Price and Fair Access for Pharmaceuticals:
The Institute for Clinical and Economic Review and Office of Health Economics White Paper Falls at the First Hurdle
Working Paper No. 21 October 2020.pdf
Adobe Acrobat document [816.6 KB]
Meaningless Magical Measures: ICER's Bizarre Belief in the EQ-5D Ratio Scale
Working Paper No. 20 September 2020.pdf
Adobe Acrobat document [904.0 KB]
Measurement Malpractice: Composite patient reported outcomes
Working Paper No. 19 August 2020.pdf
Adobe Acrobat document [707.4 KB]
The Great I-QALY Disaster (Version 2)
Working Paper No. 18 August 2020.pdf
Adobe Acrobat document [754.2 KB]
Impossible QALYs and the ICER Evidence Report for NASH: Avoiding Nonsensical Recommendations
Working Paper No. 17 July 2020.pdf
Adobe Acrobat document [623.9 KB]
Damaged Goods: Imaginary ICER value assessments and the Veterans Administration
Working Paper No. 16 July 2020.pdf
Adobe Acrobat document [631.1 KB]
The great I-QALY disaster
Working Paper No. 15 June 2020.pdf
Adobe Acrobat document [805.4 KB]
Introducing the I-QALY: The Imaginary Construct Supporting Health Technology Assessment
Working Paper No. 14 June 2020.pdf
Adobe Acrobat document [999.3 KB]
More Unnecessary Imaginary Worlds: The University of Washington Modelled Value Assessment of Targeted Immune Modulators In Ulcerative Colitis for the Institute for Clinical and Economic Review
Working Paper No. 13 May 2020.pdf
Adobe Acrobat document [1'021.2 KB]
The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds In Health Technology Assessment
Working Paper No. 12 May 2020.pdf
Adobe Acrobat document [977.9 KB]
Manifest Nonsense: Cosmin and the Axioms of Fundamental Measurement in the Checklist for Systematic Reviews
Working Paper No. 11 May 2020.pdf
Adobe Acrobat document [837.5 KB]
Evidence Framework for Rare and Chronic Diseases
Working Paper No. 10 May 2020.pdf
Adobe Acrobat document [783.0 KB]
To Dream the Impossible Dream: The EQ-5D QALY
Working Paper No. 9 April 2020 V2.pdf
Adobe Acrobat document [868.7 KB]
Post Nubes Lux: Beyond Reference Case Imaginary Worlds to Real World Evidence in Health Technology Assessment.
Working Paper No. 8 March 2020.pdf
Adobe Acrobat document [338.8 KB]
Where Ignorance is Bliss: The ICER Draft Evidence Report Modeling Imaginary Worlds for Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis (NASH) with Fibrosis
Working Paper No. 7 March 2020.pdf
Adobe Acrobat document [288.8 KB]
Working Paper No. 6 March 2020 More Unnecessary Imaginary Worlds: The ICER Final Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
Working Paper No. 6 March 2020.pdf
Adobe Acrobat document [276.8 KB]
Working Paper No. 5 March 2020 Evading the Question: The EQ-5D and ICER’s Rejection of Fundamental Measurement in Fabricating Imaginary Worlds
Working Paper No. 5 March 2020.pdf
Adobe Acrobat document [396.3 KB]
Working Paper No. 4/2020 Anticipating Imaginary Claims: The ICER Modeling Analysis Plan for Targeted Immune Modulators in Ulcerative Colitis
Working Paper No 4 March 2020.pdf
Adobe Acrobat document [237.9 KB]
Working Paper No. 3/2020 Deconstructing the Imaginary Worlds of ICER
Working Paper No. 3 2020.pdf
Adobe Acrobat document [337.4 KB]
Working Paper No.2/2020 More Unnecessary Imaginary Worlds: The Institute for Clinical and Economic Review’s Final Evidence Report and Recommendations for Acute Migraine Therapies
Working Paper No. 2 2020.pdf
Adobe Acrobat document [319.4 KB]
Working Paper No 1/2020: More Unnecessary Imaginary Worlds: Cystic Fibrosis and the Institute for Clinical and Economic Review’s Draft Evidence Report
No. 1 Cystic Fibrosis REV.pdf
Adobe Acrobat document [313.5 KB]
Print Print | Sitemap
© Maimon Research LLC